[go: up one dir, main page]

CR20210098A - COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET - Google Patents

COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET

Info

Publication number
CR20210098A
CR20210098A CR20210098A CR20210098A CR20210098A CR 20210098 A CR20210098 A CR 20210098A CR 20210098 A CR20210098 A CR 20210098A CR 20210098 A CR20210098 A CR 20210098A CR 20210098 A CR20210098 A CR 20210098A
Authority
CR
Costa Rica
Prior art keywords
sup
tam
inhibitors
pyrazolo
pyridine compounds
Prior art date
Application number
CR20210098A
Other languages
English (en)
Inventor
Shelley Allen
Ellen Laird
Adam Cook
Qian Zhao
Ronald Jay Hinklin
Joshua Dahlke
John Gaudino
Oren T Mcnulty
Patrick Barbour
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR20210098A publication Critical patent/CR20210098A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula <strong>I</strong>: y estereoisómeros, tautómeros y sales de los mismos farmacéuticamente aceptables, en donde R<sup>1</sup>, R<sup>2</sup>, R<sup>9</sup>, X<sup>1</sup> y G son como se definen en la presente, los cuales son inhibidores de una o más cinasas TAM y/o cinasa c-Met, y son útiles en el tratamiento y prevención de enfermedades las cuales pueden ser tratadas con un inhibidor de cinasa TAM y/o un inhibidor de cinasa c-Met.
CR20210098A 2018-08-30 2019-08-29 COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET CR20210098A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724829P 2018-08-30 2018-08-30
US201962858686P 2019-06-07 2019-06-07
PCT/US2019/048701 WO2020047184A1 (en) 2018-08-30 2019-08-29 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES

Publications (1)

Publication Number Publication Date
CR20210098A true CR20210098A (es) 2021-07-01

Family

ID=67928919

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210098A CR20210098A (es) 2018-08-30 2019-08-29 COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET

Country Status (24)

Country Link
US (3) US11104676B2 (es)
EP (1) EP3843850B1 (es)
JP (2) JP6970859B2 (es)
KR (1) KR20210049898A (es)
CN (1) CN112930215A (es)
AU (3) AU2019330017B2 (es)
BR (1) BR112021002722A2 (es)
CA (1) CA3110502C (es)
CL (1) CL2021000467A1 (es)
CO (1) CO2021002651A2 (es)
CR (1) CR20210098A (es)
CU (1) CU20210015A7 (es)
DO (1) DOP2021000038A (es)
EC (1) ECSP21012498A (es)
IL (1) IL281127B2 (es)
MA (1) MA53487A (es)
MX (1) MX2021001952A (es)
NI (1) NI202100007A (es)
PE (1) PE20211779A1 (es)
PH (1) PH12021500017A1 (es)
SG (1) SG11202101148UA (es)
TW (1) TW202024071A (es)
UY (1) UY38349A (es)
WO (1) WO2020047184A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020038460A1 (zh) * 2018-08-24 2020-02-27 南京药捷安康生物科技有限公司 一种新型的喹啉衍生物抑制剂
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
JP7542613B2 (ja) * 2019-09-06 2024-08-30 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ Ａｘｌとｃ－Ｍｅｔキナーゼ阻害活性を有する化合物およびその製造と使用
JP2022549678A (ja) * 2019-09-24 2022-11-28 薬捷安康（南京）科技股▲分▼有限公司 複素環誘導体及びその使用
WO2021176330A1 (en) * 2020-03-03 2021-09-10 Array Biopharma Inc. Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
US20230279024A1 (en) * 2020-07-10 2023-09-07 Beijing Findcure Biosciences, Ltd. Triazine compound and composition and use thereof
CA3214399A1 (en) * 2021-04-09 2022-10-13 Frank Perabo Treatment of cancer with kdm4 inhibitors
KR20220170766A (ko) * 2021-06-22 2022-12-30 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
WO2023002360A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Solid forms and formulations of an inhibitor of tam and c-met kinases
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN115850301B (zh) * 2021-09-24 2024-11-15 中山医诺维申新药研发有限公司 吡唑酮类化合物及其组合物和用途
JP2024540396A (ja) * 2021-11-05 2024-10-31 ハイファ バイオファーマ カンパニー リミテッド 固体分散体、その製造方法及びそれを含む固形製剤
JP2024540399A (ja) * 2021-11-05 2024-10-31 ハイファ バイオファーマ カンパニー リミテッド Ｍｅｔ受容体チロシンキナーゼ阻害剤を含む薬物の組み合わせ及びその使用
CA3240907A1 (en) 2021-12-16 2023-06-22 Xiaohu S. OUYANG Inhibitors of met kinase
JP2025501305A (ja) * 2021-12-29 2025-01-17 北京鞍石生物科技有限▲責▼任公司 ヘテロ芳香族窒素酸化物化合物、その調製方法及びその使用
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
MX2008011220A (es) * 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
WO2013032797A2 (en) * 2011-08-26 2013-03-07 New Hope R & D Bioscience, Inc. Oxetane 3,3-dicarboxamide compounds and methods of making and using same
KR20140064971A (ko) * 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
WO2013074633A1 (en) * 2011-11-14 2013-05-23 Cephalon, Inc. Uracil derivatives as axl and c-met kinase inhibitors
EP3027623A4 (en) 2013-08-02 2017-03-01 Ignyta, Inc. METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
US9914731B2 (en) * 2013-12-26 2018-03-13 Ignyta, Inc. Pyrazolo[1,5-a]pyridine derivatives and methods of their use
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
KR101829998B1 (ko) 2015-11-04 2018-02-19 롬엔드하스전자재료코리아유한회사 착색 감광성 수지 조성물 및 이를 이용한 차광성 스페이서
MD3436461T2 (ro) 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
EP3490676A1 (en) 2016-07-29 2019-06-05 Eli Lilly and Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
EP3490561A4 (en) 2016-08-01 2020-04-08 Ignyta, Inc. COMBINATIONS FOR THE TREATMENT OF CANCER
WO2018039275A1 (en) 2016-08-24 2018-03-01 Ignyta, Inc. Combinations for the treatment of cancer
JP2019536771A (ja) 2016-11-16 2019-12-19 イーライ リリー アンド カンパニー エクソン１４スキッピング変異またはエクソン１４スキッピング表現型を有する癌の治療
CN108250200A (zh) 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
JP7377798B2 (ja) 2017-11-24 2023-11-10 南京明徳新薬研発有限公司 ｃ－ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物
US11247990B1 (en) 2017-12-07 2022-02-15 Array Biopharma Inc Bicyclic fused pyridine compounds as inhibitors of TAM kinases

Also Published As

Publication number Publication date
CU20210015A7 (es) 2021-10-12
PH12021500017A1 (en) 2021-09-13
CA3110502C (en) 2023-10-03
JP2021527114A (ja) 2021-10-11
JP2022009720A (ja) 2022-01-14
US20230011441A1 (en) 2023-01-12
EP3843850A1 (en) 2021-07-07
US11104676B2 (en) 2021-08-31
TW202024071A (zh) 2020-07-01
UY38349A (es) 2020-03-31
PE20211779A1 (es) 2021-09-08
US20200079770A1 (en) 2020-03-12
WO2020047184A1 (en) 2020-03-05
ECSP21012498A (es) 2021-03-31
SG11202101148UA (en) 2021-04-29
AU2022221514A1 (en) 2022-09-22
JP6970859B2 (ja) 2021-11-24
AU2019330017B2 (en) 2022-05-26
CN112930215A (zh) 2021-06-08
NI202100007A (es) 2021-06-22
IL281127A (en) 2021-04-29
US20240174666A1 (en) 2024-05-30
CO2021002651A2 (es) 2021-03-08
MA53487A (fr) 2021-12-08
AU2022221514B2 (en) 2023-11-02
CA3110502A1 (en) 2020-03-05
KR20210049898A (ko) 2021-05-06
MX2021001952A (es) 2021-04-19
US11780835B2 (en) 2023-10-10
AU2019330017A1 (en) 2021-03-04
DOP2021000038A (es) 2021-04-15
AU2022202946A1 (en) 2022-05-26
AU2022202946B2 (en) 2023-08-03
BR112021002722A2 (pt) 2021-08-10
IL281127B1 (en) 2023-12-01
CL2021000467A1 (es) 2021-10-22
IL281127B2 (en) 2024-04-01
JP7337133B2 (ja) 2023-09-01
EP3843850B1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
CR20210098A (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
SA519401541B1 (ar) [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2021013993A (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina.
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
UA106054C2 (uk) ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИМІДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ TРK-КІНАЗИ
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
WO2012158413A3 (en) Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
NZ738280A (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
PH12021551590A1 (en) Quinoline compounds as inhibitors of tam and met kinases
EA201990940A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA202190393A1 (ru) СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TAM- И Met-КИНАЗ
MY156466A (en) Aminothiazoles and their uses
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch (&#34;nack&#34;) y metodos para el uso de los mismos.
EA201990939A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
UA100999C2 (ru) Аминотиазолы и их применение